Faeth Therapeutics, Inc (FTH) FinancialsFTHFinancialFaeth Therapeutics, Inc

Evaluating the bottom line, Faeth Therapeutics, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -195.26%, provide a clear picture of how effectively FTH converts its operational activities into shareholder value.

In the context of the broader market, FTH competes directly with industry leaders such as SGP and CLYM. With a market capitalization of $835.68M, it holds a significant position in the sector. When comparing efficiency, FTH's gross margin of N/A stands against SGP's N/A and CLYM's N/A. Such benchmarking helps identify whether Faeth Therapeutics, Inc is trading at a premium or discount relative to its financial performance.

Faeth Therapeutics has shown a substantial increase in cash position, ending Q2 2026 with $186.4 million compared to $21.2 million at the end of 2025. However, the company reported a net loss of $16 million in Q2 2026, up from a loss of $4.9 million in the same period last year, reflecting increased R&D and administrative expenses.